Screening for Early Diagnosis of Nose Cancer

Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding out how effective screening methods are for detecting nasopharyngeal cancer (NPC), a type of nose cancer, early on. Researchers are particularly interested in using tests that look for certain markers from the Epstein-Barr virus (EBV), which is linked to NPC. In this study, participants will have their risk for NPC assessed using blood tests that check for EBV proteins and DNA. If someone is identified as high risk, they will have further examinations, including a check of their head and neck and possibly a biopsy. Those at low risk will receive regular phone calls to monitor their health over the next few years.

To be eligible for this trial, participants should be between the ages of 35 and 60, of Chinese, Malay, or mixed ethnicity, and not already diagnosed with NPC. Those with a family history of NPC can participate, while pregnant women and individuals already diagnosed with NPC cannot. If you join, you can expect to have yearly check-ins and tests to help doctors learn more about NPC and how to detect it early in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chinese, Malay, and mixed ethnicities
• • individuals not diagnosed with NPC
• • individuals with family history of NPC
• Exclusion Criteria:
• • younger than 35, older than 60
• • individuals already diagnosed with NPC
• • pregnant women